AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Neurocrine Biosciences: Morgan Stanley raises PT to $163 from $158 to Overweight.
ByAinvest
Friday, Sep 5, 2025 8:50 am ET1min read
Neurocrine Biosciences: Morgan Stanley raises PT to $163 from $158 to Overweight.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a neuroscience-focused biopharmaceutical company, has seen its price target raised by Morgan Stanley to $163 from $158, with the investment bank upgrading its rating to Overweight. The move comes amidst strong performance and a robust pipeline of therapeutic candidates, particularly for neurological, neuroendocrine, and neuropsychiatric disorders.According to the latest information from the company's presentation at the Cantor Global Healthcare Conference 2025, Neurocrine Biosciences has been experiencing significant growth, especially with its flagship product, INGREZZA. The company expects $2.5 billion in sales for INGREZZA in 2025, driven by strong patient starts and the successful launch of its new medication, CRENESSITY, which is the first new medicine in over 70 years for patients with congenital adrenal hyperplasia.
The company also highlighted its Phase III programs for osavampator in major depressive disorder and its muscarinic program for schizophrenia and bipolar mania, both of which are showing promising progress. These initiatives, combined with the company's strong financial position and flexibility for future investments, have contributed to the positive outlook from Morgan Stanley.
The investment bank's upgrade reflects its confidence in Neurocrine Biosciences' ability to capitalize on market opportunities and maintain its momentum. The company's strategic approach to contracting and formulary coverage, particularly for INGREZZA, has been instrumental in driving growth and reducing barriers to patient access.
References:
[1] https://www.marketscreener.com/news/rbc-raises-price-target-on-neurocrine-biosciences-to-149-from-144-keeps-outperform-rating-ce7d59d9d88ef42d
[2] https://seekingalpha.com/article/4819113-neurocrine-biosciences-inc-nbix-presents-at-cantor-global-healthcare-conference-2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet